Showing 1551-1560 of 10035 results for "".
FDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/series/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.FDA Approves Rosacea Treatment Emrosi
https://practicaldermatology.com/series/dermwire-tv/fda-approves-rosacea-treatment-emrosi/29207/In this week's DermwireTV, the FDA approves a first-of-its-kind treatment for rosacea in adults; two companies with approved atopic dermatitis products provide new long-term efficacy and safety data; and Andrew Mastro discusses how to recognize physician burnout.Significant FDA Approval for PDT
https://practicaldermatology.com/series/pdt-in-practice/significant-fda-approval-pdt/29102/Dr. Jonathan S. Weiss discusses the importance of a recent FDA approval involving dosing of a PDT photosensitizer for both lesion-directed and field-directed treatment of actinic keratosis.Understanding Disparities in AD
https://practicaldermatology.com/series/updates-atopic-dermatitis/understanding-disparities-ad/29081/Dr. Raj Chovatiya, Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research, talks with Practical Dermatology about understanding disparities in atopic dermatitis and the socHow to Approach a Contract Negotiation
https://practicaldermatology.com/series/pa-perspectives/how-approach-contract-negotiation/29072/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, provides tips on how to approach a contract negotiation, including the importance of using objective data while negotiating.DermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologies with AvitDERM2021: The Right Meeting For All Derm PAs/NPs
https://practicaldermatology.com/series/dermatology-education-foundation/derm2021-the-right-meeting-for-all-derm-pasnps/19964/Kristine Kucera, PA-C, MPAS, DHS says all dermatology physician assistants and nurse practitioners should be attending this year’s DERM2021 NP/PA CME Conference. She discusses the unique educational opportunities and access to top-notch presenters available at this meeting.Seeing the Individual in AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/seeing-the-individual-in-ad-care/19890/The best care for patients with atopic dermatitis requires a holistic approach, suggests Dr. Stephan Weidinger. He discusses strategies to improve the management of this complex diseases and highlights innovative strategies for care identified through the Quality of Care in Atopic Dermatitis initiatLearn More About REVIAN® Red Hair Growth System
https://practicaldermatology.com/topics/hair-nails/learn-more-about-revian-red-hair-growth-system/19750/Discover a new option for hair loss patients! REVIAN Red is a patented dual-band LED wireless cap for at-home use ten minutes daily. Click Here to Become a REVIAN Red Professional. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton clDermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abbvie-to-acquire-allergan-duobrii-launches-sdpa-at-25/19629/In a deal with an equity value of approximately $63 billion, AbbVie has agreed to acquire Allergan. The new company is positioned for new growth platforms and a diversified revenue base; the deal will be immediately accretive to earnings per share, AbbVie says. The Society of Dermatology Physician A